SCHEMBL3783236

SCHEMBL3783236

FC(F)(F)Cc1cccc(CNCC2C3CNCC23)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CXCR4 P61073 1/20 0.33
MAN1B1 Q9UKM7 1/20 0.33
MC4R P32245 1/20 0.33
PRMT5 O14744 1/20 0.32
WDR77 Q9BQA1 1/20 0.32
NOS1 P29475 1/20 0.32
NOS2 P35228 1/20 0.32
ENPP2 Q13822 1/20 0.32
DPP7 Q9UHL4 1/20 0.32
HTR2A P28223 1/20 0.31
HTR2C P28335 1/20 0.31
HTR2B P41595 1/20 0.31
CETP P11597 1/20 0.30
CHRNB2 P17787 1/20 0.30
CHRNB4 P30926 1/20 0.30
CHRNA3 P32297 1/20 0.30
CHRNA4 P43681 1/20 0.30
METTL3 Q86U44 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5513104 0.84 DPP7 (0.47) NOS1NOS2DPP7HTR2AHTR2C
Hydrochloric Acid SCHEMBL709536 0.83 DPP7 (0.46) NOS1NOS2DPP7HTR2AHTR2C
SCHEMBL3778065 0.82 ATM (0.36) ATML3MBTL1CXCR4ENPP2
SCHEMBL5506384 0.81 SLC6A9 (0.46) HTR2CCETP
SCHEMBL3765708 0.81 BCHE (0.33) ATML3MBTL1MAN1B1PRMT5WDR77
Hydrochloric Acid SCHEMBL709983 0.80 SLC6A9 (0.45) HTR2CCETP
SCHEMBL15967360 0.79 CHRM2 (0.50) CXCR4NOS1HTR2CHTR2B
SCHEMBL708596 0.78 CXCR4 (0.46) CXCR4MAN1B1MC4RHTR2C
Hydrochloric Acid SCHEMBL708458 0.78 CHRM2 (0.49) CXCR4NOS1NOS2
SCHEMBL3783233 0.77 HDAC6 (0.44) ENPP2HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1869019-B1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS PFIZER PROD INC (US) 2014-08-27 EP claimed
EP-1869019-A1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS Pfizer Products Incorporated (US) 2007-12-26 EP claimed
WO-2006106425-A1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS PFIZER PRODUCTS INC. (US) 2006-10-12 WO claimed
EP-1869019-B1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS PFIZER PROD INC (US) 2014-08-27 EP disclosed
US-20100324020-A1 Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors PFIZER INC. 2010-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324020-A1 Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors SLC1A2, SLC1A1, SLC6A5 ATM 4469/4885L3MBTL1 1700/4885CXCR4 815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.